Radalbuvir is a small molecule inhibitor and broad-spectrum antiviral designed to target the polymerase involved in hepatitis C virus replication, having been investigated in clinical trials for the treatment… Read more
Radalbuvir is a small molecule inhibitor and broad-spectrum antiviral designed to target the polymerase involved in hepatitis C virus replication, having been investigated in clinical trials for the treatment of chronic Hepatitis C infection. This category provides access to high-quality reference standards for Radalbuvir, including its pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. Pharmaceutical and analytical laboratories rely on these specialized materials to conduct rigorous impurity profiling, perform method validation, and ensure stringent quality control throughout the drug development lifecycle. By utilizing these precisely characterized reference standards, researchers can accurately identify, quantify, and monitor the chemical profile of Radalbuvir and its associated compounds during stability testing and routine analytical analysis.